You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):子公司的他氟前列素滴眼液獲得藥品註冊證書
格隆匯 11-12 18:03

格隆匯11月12日丨恆瑞醫藥(600276.SH)公佈,近日,公司子公司成都盛迪醫藥有限公司收到國家藥品監督管理局核准簽發的《藥品註冊證書》。藥品名稱:他氟前列素滴眼液。

他氟前列素為前列腺素類似物,是一種選擇性FP前列腺素類受體激動劑,可通過增加葡萄膜鞏膜途徑房水流出量來降低眼內壓,適用於降低開角型青光眼和高眼壓症患者升高的眼壓。他氟前列素滴眼液由參天製藥株式會社開發,於2012年2月在美國獲批,現已在中國獲批。

同類產品有貝美前列素滴眼液(商品名:LUMIGAN)、曲伏前列素(商品名:TRAVATANZ)和拉坦前列素(商品名:XALATAN)。經查詢,2020年他氟前列素相關劑型全球銷售額約為2.08億美元。

截至目前,他氟前列素滴眼液相關項目累計已投入研發費用約為1678萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account